Contineum Therapeutics, Inc.: diluted weighted-average shares
Diluted weighted-average shares for Contineum Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Contineum Therapeutics, Inc. financial histories
What this measure means
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2023-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 27,700,855 | shares | 2026-03-05 | 10-K · 0001628280-26-015165 |
| 2024-01-01 | 2024-12-31 | 19,352,859 | shares | 2026-03-05 | 10-K · 0001628280-26-015165 |
| 2023-01-01 | 2023-12-31 | 3,395,514 | shares | 2025-03-06 | 10-K · 0001437749-25-006458 |
Related financial histories
- Contineum Therapeutics, Inc.: total assets
- Contineum Therapeutics, Inc.: total liabilities
- Contineum Therapeutics, Inc.: stockholders equity
- Contineum Therapeutics, Inc.: cash and cash equivalents
- Contineum Therapeutics, Inc.: net income or loss
- Contineum Therapeutics, Inc.: operating cash flow
- Contineum Therapeutics, Inc.: capital expenditure payments
- Contineum Therapeutics, Inc.: financing cash flow
- Contineum Therapeutics, Inc.: investing cash flow
- Contineum Therapeutics, Inc.: retained earnings or deficit
- Contineum Therapeutics, Inc.: basic weighted-average shares
- Contineum Therapeutics, Inc.: basic earnings per share
- Contineum Therapeutics, Inc.: diluted earnings per share
- Contineum Therapeutics, Inc.: income tax expense or benefit
- Contineum Therapeutics, Inc.: net property, plant and equipment
- Contineum Therapeutics, Inc.: share-based compensation expense
- Contineum Therapeutics, Inc.: operating income or loss
- Contineum Therapeutics, Inc.: current assets
- Contineum Therapeutics, Inc.: current liabilities
- Contineum Therapeutics, Inc.: current accounts payable
- Contineum Therapeutics, Inc.: operating expenses
- Contineum Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Contineum Therapeutics, Inc. / CIK 0001855175
- Captured
- 2026-09-21T17:31:26.057Z
- SEC response SHA-256
760edf4abeba0b9b3b707ba68ea66f62dfa545453df5a2fcf6691ed348669d76
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001855175.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))